eligibility_summary
Adults ≥18 with ECOG 0–2 and histologically/cytologically confirmed locally advanced/metastatic solid tumors with HER2 IHC 2+ or 3+. Prior standard 1st-line therapy required (cohorts 1–2: trastuzumab+chemo for HER2+, IO+chemo or chemo for IHC2+/FISH−, cohort 3: guideline 1st-line) and documented progression. RECIST 1.1 measurable/evaluable disease, consent, expected benefit, compliance, records. Exclude drug hypersensitivity, other trials, or investigator unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Prospective, non-interventional real-world study in China of second-line+ treatments for HER2-overexpressed advanced gastric/GEJ adenocarcinoma and other solid tumors after first-line failure. Main drug: Disitamab Vedotin (RC48), an anti-HER2 antibody–drug conjugate (ADC) carrying MMAE, it binds HER2 on tumor cells, is internalized, releases MMAE to disrupt microtubules, and can induce ADCC. Some patients also receive investigator-selected regimens: chemotherapy (paclitaxel/docetaxel—taxane microtubule stabilizers, irinotecan—topoisomerase I inhibitor, fluorouracil—thymidylate synthase inhibitor), targeted anti-angiogenics (apatinib—VEGFR2 TKI, ramucirumab—VEGFR2 mAb), and immune checkpoint inhibitors (anti-PD-1/PD-L1 mAbs). Targets/pathways: HER2+ tumor cells, microtubules, DNA replication/synthesis, VEGFR2-mediated angiogenesis, and the PD-1/PD-L1 T-cell checkpoint.